Ipamorelin pharmacokinetic-pharmacodynamic study in human volunteers
PubMed
TL;DR
Ipamorelin produced a clear dose-related pulse of growth hormone in healthy men and had an estimated terminal half-life of about two hours.
Human dose-escalation PK/PD study · 5 dose levels
What was studied
The question.
How ipamorelin behaves in the body and how strongly different exposures stimulate growth-hormone release.
How it was conducted
The study design.
Healthy male volunteers received 15-minute ipamorelin infusions across five escalating dose levels, with eight subjects at each level. Researchers repeatedly measured ipamorelin and GH concentrations and modeled the PK/PD relationship.
What it found
Did it actually work?
- Ipamorelin exposure increased proportionally with dose.
- GH release appeared as a single pulse, peaking at about 0.67 hours.
- The estimated terminal half-life was about two hours.
Why it matters
How to read this result.
It confirms direct human GH-releasing pharmacology for ipamorelin and helps separate evidence for the individual component from claims about popular CJC/ipamorelin combinations.
Keep in mind
What the study does not prove.
- The study focused on pharmacology rather than long-term clinical outcomes.
- It does not establish the efficacy of combining ipamorelin with CJC-1295 or Mod GRF.
Original source
Want to read the original?
We summarize the study here first. The original source is there when you want the full methods, statistics, tables and author discussion.
Open the journal article